Back to Portfolio

Novo Nordisk Financial Analysis

Strategic analysis of Novo Nordisk - Denmark's pharmaceutical leader and GLP-1 innovator. This dashboard provides insights into financial performance, competitive positioning, R&D efficiency, and market dynamics.

Analysis Methodology

Data Sources

  • Yahoo Finance: Financial statements & stock prices (2015-2024)
  • Financial Modeling Prep: Supplementary ratios
  • Eurostat: Healthcare & pharmaceutical market data
  • Danish Statistics: R&D expenditure & employment data

Key Metrics

  • Profitability: Margins, ROE, ROA, ROIC
  • Liquidity: Current, Quick, Cash ratios
  • Leverage: Debt-to-Equity, Debt-to-Assets
  • Growth: Revenue, Net Income, FCF trends

Strategic Financials Dashboard

Comprehensive analysis covering market positioning, financial fundamentals, and capital allocation strategies.

Novo Nordisk Strategic Financials Dashboard

Innovation & R&D Focus

Analysis of R&D investment, efficiency, and innovation returns compared to industry peers.

Novo Nordisk Innovation & R&D Dashboard

Peer Comparison

This analysis compares Novo Nordisk against key competitors including Eli Lilly (LLY), Sanofi (SNY), AstraZeneca (AZN), Novartis (NVS), and Bayer (BAYRY) across multiple financial dimensions including market positioning, profitability, R&D efficiency, and capital allocation.